These cases include individuals with varying clinical characteristics, such as advanced disease stages in PSP cases, older age or cognitive decline in AD cases, and pathogenic mutations (e.g., TBK1, MAPT) in FTD cases. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.